Page last updated: 2024-08-18

thiophenes and Hypertension, Portal

thiophenes has been researched along with Hypertension, Portal in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hou, MC; Hsieh, YC; Huang, CC; Huang, SF; Huang, YH; Lee, KC; Li, TH; Lin, HC; Liu, RS; Tsai, HC; Yang, YY	1
Cima, K; Desole, S; Graziadei, I; Kähler, CM; Vogel, W; Vogelsinger, H	1
Brouard, R; Caillau, H; Calès, P; Crambes, O; Desmorat, H; Jung, L; Pascal, JP; Rocher, I; Urien, S; Vinel, JP	1

Trials

1 trial(s) available for thiophenes and Hypertension, Portal

Article	Year
Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension. Journal of hepatology, 1993, Volume: 19, Issue:1 Topics: Adrenergic beta-Antagonists; Female; Hemodynamics; Humans; Hypertension, Portal; Liver Cirrhosis, Alcoholic; Male; Middle Aged; Propanolamines; Propranolol; Thiophenes	1993

Other Studies

2 other study(ies) available for thiophenes and Hypertension, Portal

Article	Year
Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension. The American journal of pathology, 2018, Volume: 188, Issue:7 Topics: Animals; Caco-2 Cells; Humans; Hypertension, Portal; Liver Circulation; Liver Cirrhosis; Male; Neovascularization, Pathologic; Oxazoles; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Splanchnic Circulation; Thiophenes	2018
Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan. Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:7-8 Topics: Endothelin Receptor Antagonists; Humans; Hypertension, Portal; Hypertension, Pulmonary; Isoxazoles; Male; Pilot Projects; Syndrome; Thiophenes; Treatment Outcome; Young Adult	2011

Article

Year

Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension.

The American journal of pathology, 2018, Volume: 188, Issue:7

Topics: Animals; Caco-2 Cells; Humans; Hypertension, Portal; Liver Circulation; Liver Cirrhosis; Male; Neovascularization, Pathologic; Oxazoles; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Splanchnic Circulation; Thiophenes

2018

Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan.

Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:7-8

Topics: Endothelin Receptor Antagonists; Humans; Hypertension, Portal; Hypertension, Pulmonary; Isoxazoles; Male; Pilot Projects; Syndrome; Thiophenes; Treatment Outcome; Young Adult

2011